|
Treatment strategy
|
Comparator
|
Odds ratio
|
Standard error
|
95% Confidence interval
|
|---|
|
Adalimumab
|
Infliximab
|
0.57
|
0.57
|
0.18
|
1.74
|
|
Certolizumab pegol
|
Infliximab
|
1.74
|
0.67
|
0.47
|
6.53
|
|
Natalizumab
|
Infliximab
|
0.58
|
0.60
|
0.18
|
1.88
|
|
Ustekinumab
|
Infliximab
|
0.30
|
0.66
|
0.08
|
1.08
|
|
Vedolizumab
|
Infliximab
|
0.55
|
0.58
|
0.18
|
1.74
|
|
Golimumab
|
Infliximab
|
1.26
|
0.80
|
0.26
|
6.05
|
|
Infliximab + azathioprine/6MP
|
Infliximab
|
0.81
|
0.50
|
0.30
|
2.17
|
|
Infliximab + azathioprine/6MP + prednisone
|
Infliximab
|
0.23
|
2.29
|
0.00
|
20.82
|
|
Certolizumab pegol
|
Adalimumab
|
3.08
|
0.62
|
0.91
|
10.37
|
|
Natalizumab
|
Adalimumab
|
1.03
|
0.54
|
0.36
|
2.94
|
|
Ustekinumab
|
Adalimumab
|
0.52
|
0.60
|
0.16
|
1.71
|
|
Vedolizumab
|
Adalimumab
|
0.98
|
0.52
|
0.35
|
2.71
|
|
Golimumab
|
Adalimumab
|
2.22
|
0.76
|
0.50
|
9.78
|
|
Natalizumab
|
Certolizumab pegol
|
0.34
|
0.64
|
0.10
|
1.18
|
|
Ustekinumab
|
Certolizumab pegol
|
0.17
|
0.70
|
0.04
|
0.67
|
|
Vedolizumab
|
Certolizumab pegol
|
0.32
|
0.63
|
0.09
|
1.09
|
|
Golimumab
|
Certolizumab pegol
|
0.72
|
0.84
|
0.14
|
3.71
|
-
Abbreviations: 6MP 6-mercaptopurine, MMF mycophenolate mofetil
-
aOther group comparisons can be found in Additional file 3: Table S3
